JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval

Still basking in an FDA approval for its second RNAi therapy, Givlaari, Alnylam is looking ahead to a series of launches that could vault its business far ahead of where it is now. So far, in fact, that CEO John Maraganore sees Alnylam rising to biotech's top ranks.